[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Koo Foundation Sun Yat-Sen Cancer Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":132},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,79,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100631399","fighting-the-fear-of-cancer-recurrence-in-cancer-survivors-a-pilot-study-on-the-effectiveness-of-metacognitive-therapy-100631399",false,"NCT07500168","Fighting the Fear of Cancer Recurrence in Cancer Survivors: A Pilot Study on the Effectiveness of Metacognitive Therapy","MCT-FCR","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Patients with cancer classified as stage I, II, or III according to the TNM staging system who have completed primary cancer treatment.\n3. Ability to understand and read Chinese, with no significant cognitive impairment.\n4. A score of 13 or higher on a validated measure of fear of cancer recurrence.\n\nExclusion Criteria:\n\n1. Individuals with severe psychiatric disorders.\n2. Individuals who have difficulty communicating in Mandarin. -","ALL","18 Years",{"count":19,"type":20},120,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aims to evaluate the effectiveness of metacognitive therapy (MCT) in reducing fear of cancer recurrence (FCR) among cancer survivors.\n\nWith advances in cancer treatment, more patients are surviving cancer. However, many survivors continue to experience fear of cancer recurrence, which can affect their emotional well-being, quality of life, and ability to return to normal daily activities.\n\nIn this study, participants will receive a structured psychological intervention adapted from the ConquerFear program. This program has been modified to better fit local cultural needs.\n\nParticipants will be randomly assigned to receive either metacognitive therapy or relaxation therapy.\n\nThe study will compare the effects of these interventions on reducing fear of cancer recurrence, as well as their impact on emotional distress and quality of life.\n\nThe results of this study may help develop effective psychological treatments to support cancer survivors in managing fear of recurrence and improving overall well-being.",[26,27,28],"Fear of Cancer Recurrence","Cancer Survivors","Psychological Distress",[26,27,30,31,32,33,34,35],"Psycho-oncology","ConquerFear","Randomized Controlled Trial","Anxiety","Depression","Quality of Life","NOT_YET_RECRUITING","2026-03-24",{"date":39,"type":40},"2026-03-30","ACTUAL",{"date":42,"type":20},"2026-04",{"date":44,"type":20},"2028-12-31",{"name":46,"class":47},"Koo Foundation Sun Yat-Sen Cancer Center","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":5},"100408665","early-phase-1-hepatic-ia-therapy-in-stage-b-or-limited-stage-c-hepatoma-hcc-100408665","NCT04601428","Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC)","CSR02-Fab-TF as Hepatic Intra-arterial Therapy in Intermediate Stage B or Limited Advanced Stage C Hepatocellular Carcinoma (HCC): Dose-Escalation Study to Assess Safety and Tolerability","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of HCC by at least one of the following criteria:\n\n  * Histological confirmation;\n  * Magnetic resonance imaging (MRI) or computerized tomography (CT) consistent with liver cirrhosis AND at least one solid liver lesion \\> 1 cm with intense contrast uptake during the arterial phase followed by contrast washout during the venous phase regardless of alpha-fetal protein (AFP) level\n* Barcelona Clinic Liver Cancer (BCLC) Intermediate Stage B or limited Advanced Stage C (see Protocol Section 3.1). Patients with Stage C disease should have received or been offered and chosen not to receive systemic therapy\n* Inadequate response to prior liver-directed therapy (e.g., TACE, bland embolization, Y90, ablation, radiation therapy) to the same targeted area or progressive disease after prior liver-directed therapy) or to one or more systemic therapies\n* Not a candidate for curative resection, liver transplantation, or percutaneous ablation (See Protocol Appendix 3)\n* Eastern Collective Oncology Group (ECOG) performance status ≤1 (See Protocol Appendix 5)\n* Adequate laboratory parameters, including:\n\n  * Serum total bilirubin ≤ 2x ULN\n  * Alkaline phosphatase, aspartate aminotransferase (AST) and aspartate aminotransferase (ALT) \\\u003C 5 x ULN;\n  * Serum creatinine ≤ 1.5 mg\u002FdL;\n  * Prothrombin time (international normalized ratio; INR) ≤ 1.5;\n  * Absolute neutrophil count \\> 1000\u002FμL;\n  * Platelet count \\> 75,000\u002FμL;\n  * Hgb \\> 8 g\u002FdL\n* Acceptable pulmonary status, including room air O2 saturation \\> 90%\n* Child-Pugh A-B7 without clinically significant ascites (See Protocol Appendix 4)\n* Signed informed consent\n* All subjects must be surgically sterile, at least two years post-menopausal (if female), or agree to use adequate, effective contraception approved by the Investigator until two (2) months after receiving a final dose of CSR02-Fab-TF\n\nExclusion Criteria:\n\n* Eligible for transplantation by Milan criteria (Protocol Appendix 3) or potentially eligible if successfully \"down staged\" by pre-transplant therapy\n* Prior organ transplantation\n* Any small molecule drug treatment for HCC (including TACE) within the previous 30 days, treatment with biological agents or any investigational therapy within the previous 60 days, or treatment with Y90 within the previous 90 days.\n* Previously treated malignancies from which the subject has not been disease-free for at least 2 years, except for adequately treated non-melanoma skin cancer, in situ cancer, or low-grade prostate or bladder cancer\n* Severe chronic obstructive or other pulmonary disease with hypoxemia that requires supplementary oxygen or clinically significant pleural effusions\n* New York Heart Association (NYHA) Class III or IV, cardiac disease, myocardial infarction within 3 months prior to therapy, unstable arrhythmia, symptomatic peripheral arterial vascular disease, or presence of an artificial or other vascular device requiring chronic anticoagulation (See Protocol Appendix 6)\n* Any of the following risks related to QT\u002FQTc interval:\n\n  * Baseline prolongation of QT\u002FQTc interval (repeated interval \\> 480 milliseconds using Frederica's QT correction formula);\n  * History of additional risk factors for Torsades de Pointes (e.g. heart failure, hypokalemia, family history of Long QT syndrome);\n  * Concomitant medications that have a known risk for prolongation of the QT\u002FQTc interval (see https:\u002F\u002Fcrediblemeds.org\u002Fnew-drug-list\u002F)\n* Major surgery, vascular injury, or serious illness within the previous 60 days\n* Known inherited thrombophilia (hypercoagulable state) or history of unprovoked venous or arterial thrombosis\n* Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy at screening. Subjects with prior HBV (positive HBSAg) must have HBV viral load \\\u003C 2000 IU\u002FmL or be receiving concurrent anti-HBV therapy to be eligible. Subjects on anti-HBV therapy must have been on treatment with a viral load maintained at \\\u003C 2000 IU\u002FmL for at least 4 weeks prior to first dose and continue on this same therapy throughout study treatment. Subjects with HCV infection are eligible if other eligibility criteria are met\n* Females who are breast-feeding\n* Allergy to iodinated contrast medium that is uncontrolled or refractory to medical therapy\n* Therapeutic anticoagulation that cannot be stopped 24-72 hours before treatment (per Section 4.5) and reinstituted no sooner than 72 hours after therapy\n* Any concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this study\n* Unwillingness or inability to comply with the study protocol for any reason",{"count":57,"type":20},43,[59],"EARLY_PHASE1","Intra-arterial (IA) therapy is generally used to treat HCC tumors that are too extensive to excise or treat with potentially curative local therapy. IA therapy takes advantage of the fact that the blood supply of HCC comes predominantly from the hepatic artery compared with the surrounding normal liver which is predominantly supplied by portal venous blood. The intent is to deprive the HCC of its blood supply, leading to the death of the tumor. Traditionally, various methods have been used to block the HCC blood supply, but improvements are needed. This study will investigate a new agent designed in the laboratory to block only tumor blood vessels, not blood vessels in the normal liver.",[62],"Hepatocellular Carcinoma (HCC)",[64,65,66,67,68,69],"Hepatocellular carcinoma","HCC","hepatoma","IA (intra-arterial) therapy","PLVAP","CSR02-Fab-TF","RECRUITING","2025-03-04",{"date":73,"type":40},"2025-03-06",{"date":75,"type":40},"2021-01-26",{"date":77,"type":20},"2025-12",{"name":46,"class":47},{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":21,"phases":91,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":48},"100575249","ga-68-fapi-46-pet-for-crc-recurrence-detection-in-elevated-cea-100575249","NCT06769828","Ga-68-FAPI-46 PET for CRC Recurrence Detection in Elevated CEA","Diagnostic Performances of Ga-68-FAPI-46 PET in CRC Patients with Rising Serum CEA During the Post-treatment Surveillance","Ga-68-FAPI-46","Inclusion Criteria:\n\n* Age ≥ 20 years old\n* The surgical intervention for colorectal cancer aims for curative resection, with the goal of achieving a disease-free status that persists for six months or more, as assessed clinically and through imaging studies.\n* Elevated serum CEA levels:\n\nExceeding the laboratory's normal range (5 ng\u002Fml) or, but not surpassing 13 ng\u002Fml; using the individual's post-surgery +\u002F- adjuvant chemotherapy or targeted therapy minimum value as a baseline, a consecutive increase of more than 10% for two times or as determined by the attending physician suggests suspicion of recurrence.\n\n* Already performed or scheduled for FDG PET scanning examination. (5) Able to lie flat for at least 30 minutes.\n* Signing the subject consent form.\n* ECOG grade 0-2.\n* The timing of F-18-FDG usage in this trial follows the \" 2023 - Colorectal Cancer Treatment Principles\" of our institution.\n\nExclusion Criteria:\n\n* pregnant woman and breastfeeding women\n* severe renal impairment (eGRF\\\u003C 30ml\u002Fmin)\n* Known or suspected allergy to radiopharmaceuticals\n* Simultaneously or previously diagnosed with malignant tumors other than colorectal cancer.\n* Inability to undergo the necessary PET scan procedure\n* Refusal or unwillingness to sign the informed consent form\n* Severe medical conditions (severe disabilities, mental disorders)","20 Years","100 Years",{"count":90,"type":20},30,[23],"This single-center, phase II clinical trial investigates the diagnostic efficacy of Ga-68-FAPI-46 PET scans in detecting colorectal cancer (CRC) recurrence during post-treatment surveillance, particularly in patients with elevated serum carcinoembryonic antigen (CEA). The study compares the sensitivity, specificity, and accuracy of Ga-68-FAPI-46 PET with the conventional F-18-FDG PET scans, aiming to enhance recurrence detection in CRC patients who underwent curative surgery. Thirty participants will be enrolled and monitored through imaging studies and clinical follow-up.",[94],"Colorectal Cancer Recurrent",[96,97],"Ga-68-FAPI-46 PET\u002FCT","Colorectal cancer (CRC)","2025-01-19",{"date":100,"type":40},"2025-01-22",{"date":102,"type":20},"2025-02-01",{"date":104,"type":20},"2026-04-14",{"name":46,"class":47},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":87,"maxAge":88,"enrollmentInfo":114,"targetDuration":4,"studyType":21,"phases":116,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":48},"100551522","phase-2-ga-68-cxcr4-petct-in-indolent-b-cell-lymphoma-100551522","NCT06461182","Ga-68-CXCR4 PET\u002FCT in Indolent B-cell Lymphoma","Ga-68-CXCR4 PET\u002FCT in Detecting, Evaluating Response to Treatment, and Monitoring Risk of Aggressiveness of Indolent B-cell Lymphoma","PentixaFor","Inclusion Criteria:\n\n* The pathological diagnosis is slow-growing lymphoma, such as: marginal-zone B-cell lymphoma, Waldenstrom macroglobulinemia lymphocytic lymphoma, CLL\u002FSLL, mantle cell lymphoma.\n* Have undergone or planned to undergo FDG PET scan for indications including initial staging, therapeutic response evaluation, or follow-up examinations within 3 to 6 months in the clinical observation group.\n* Able to lie flat for at least 30 minutes.\n* Signing the subject consent form.\n* ECOG grade 0-2.\n* The timing of F-18-FDG usage in this trial follows the \"Lymphoma Treatment Principles\" of our institution.\n\nExclusion Criteria:\n\n* Pregnant woman\n* Severe renal impairment (eGRF\\\u003C 30ml\u002Fmin)\n* Known or suspected allergy to radiopharmaceuticals\n* Concurrent or previous diagnosis of malignancies other than lymphoma\n* Inability to undergo the necessary PET scan procedure\n* Refusal or unwillingness to sign the informed consent form\n* Severe medical conditions (severe disabilities, mental disorders)",{"count":115,"type":20},15,[117],"PHASE2","This study explores the efficacy of Ga-68-PentixaFor PET\u002FCT in detecting, assessing treatment response, and monitoring the risk of aggressiveness in indolent B-cell lymphoma. The background introduces CXCR4 and discusses its role in cancer research. Currently, FDG-PET is the primary imaging tool for lymphoma staging, but it lacks diagnostic accuracy for low-grade lymphomas. Ga-68-PentixaFor PET demonstrates promising detection capabilities across various lymphomas, suggesting its potential as a superior imaging modality for low-grade lymphomas.",[120],"Indolent B-Cell Non-Hodgkin Lymphoma",[122,123],"Ga-68-CXCR4 PET\u002FCT","indolent B-cell lymphoma","2024-06-11",{"date":126,"type":40},"2024-06-14",{"date":128,"type":40},"2024-04-29",{"date":130,"type":20},"2027-04",{"name":46,"class":47},""]